Literature DB >> 15086411

Guidelines on the diagnosis and management of chronic lymphocytic leukaemia.

D Oscier1, C Fegan, P Hillmen, T Illidge, S Johnson, P Maguire, E Matutes, D Milligan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15086411     DOI： 10.1111/j.1365-2141.2004.04898.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  22 in total

1.  An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia.

Authors:  William Nigel Patton; Robert Lindeman; Andrew C Butler; Thomas J Kipps; Roxanne C Jewell; Kevin H Laubscher; Yan Yan Zhou; Eric Lewis; Donna Sedoti; Philip Witman; Lei Fang; Geoffrey Chan
Journal:  Leuk Lymphoma       Date:  2015-09-02

2.  Reactivation of latent Epstein Barr virus infection induces remission of splenic lymphoma with villous lymphocytes.

Authors:  Markus Hansson; Annika Linde; Inge Olsson
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

3.  Epidemiology of non-Hodgkin lymphomas in Tyrol/Austria from 1991 to 2000.

Authors:  T Mitterlechner; M Fiegl; H Mühlböck; W Oberaigner; S Dirnhofer; A Tzankov
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

Review 4.  Best practice in primary care pathology: review 7.

Authors:  W S A Smellie; J Forth; S R S Smart; M J Galloway; W Irving; D Bareford; P O Collinson; K G Kerr; G Summerfield; P J Carey; Rubin Minhas
Journal:  J Clin Pathol       Date:  2006-10-17       Impact factor: 3.411

5.  Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia.

Authors:  Keith Tolley; Catherine Goad; Yunni Yi; Penny Maroudas; Amin Haiderali; Gwilym Thompson
Journal:  Eur J Health Econ       Date:  2012-09-01

6.  Chronic lymphocytic leukemia in Korean patients: frequent atypical immunophenotype and relatively aggressive clinical behavior.

Authors:  Mi-Ae Jang; Eun-Hyung Yoo; Kihyun Kim; Won Seog Kim; Chul Won Jung; Sun-Hee Kim; Hee-Jin Kim
Journal:  Int J Hematol       Date:  2013-02-12       Impact factor: 2.490

7.  Modelling the cost effectiveness of rituximab in chronic lymphocytic leukaemia in first-line therapy and following relapse.

Authors:  Michael Adena; Jennifer Houltram; Stephen P Mulligan; Carlene Todd; Grace Malanos
Journal:  Pharmacoeconomics       Date:  2014-02       Impact factor: 4.981

Review 8.  Management of paraproteinaemia.

Authors:  Lucy Cook; Donald H C Macdonald
Journal:  Postgrad Med J       Date:  2007-04       Impact factor: 2.401

9.  Economic evaluation of third-line treatment with alemtuzumab for chronic lymphocytic leukaemia.

Authors:  W Guy Scott; Helen M Scott
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

10.  Treatment options for high-risk chronic lymphocytic leukaemia.

Authors:  Saman Hewamana; Claire Dearden
Journal:  Ther Adv Hematol       Date:  2011-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.